More than half (52%) of the $81 billion that U.S. pharmacies and health care providers collected in 2020 in reimbursement from payers for brand-name prescription drugs came through pharmacy and provider participation in the 340B program, up from 14% of the $24.7 billion they took in 2013, according to a new drug industry-funded study.
The American Hospital Association (AHA) dismissed the study as an attempt by brand drug manufacturers to deflect attention from their primary responsibility for high drug prices.
More than half (52%) of the $81 billion that U.S. pharmacies and health care providers collected in 2020 in reimbursement from payers for brand-name prescription drugs came through pharmacy and provider participation in the 340B program, up from 14% of the $24.7 billion they took in 2013, according to a new drug industry-funded study.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
